{"id":"floctafenine","rwe":[{"pmid":"41606487","year":"2026","title":"Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.","finding":"","journal":"BMC cardiovascular disorders","studyType":"Clinical Study"},{"pmid":"33050924","year":"2020","title":"Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).","finding":"","journal":"Trials","studyType":"Clinical Study"},{"pmid":"31185391","year":"2019","title":"Design, synthesis, modeling studies and biological screening of novel pyrazole derivatives as potential analgesic and anti-inflammatory agents.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"},{"pmid":"30417793","year":"2019","title":"Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity.","finding":"","journal":"Current clinical pharmacology","studyType":"Clinical Study"},{"pmid":"29528082","year":"2018","title":"Iron-catalyzed ortho trifluoromethylation of anilines via picolinamide assisted photoinduced C-H functionalization.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"}],"tags":[{"label":"floctafenine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 1","category":"target"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"N02BG04","category":"atc"},{"label":"Active","category":"status"},{"label":"Acute pain","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"idarac","offLabel":[],"synonyms":["idarac","floctafenine","diralgan","floctafenin","novodolan"],"timeline":[],"approvals":[],"brandName":"Idarac","ecosystem":[{"indication":"Acute pain","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin G/H synthase 1","targets":[{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"}],"modality":"Small Molecule","drugClass":"floctafenine","explanation":"Imagine your body has a messaging system that sends pain signals to your brain. Prostaglandins are like the messengers that carry these pain signals. Idarac blocks the production of these messengers, which helps to reduce pain.","oneSentence":"Idarac works by blocking the production of prostaglandins, which are chemical messengers that transmit pain signals to the brain.","technicalDetail":"Idarac specifically targets Prostaglandin G/H synthase 1, an enzyme involved in the conversion of arachidonic acid to prostaglandins, thereby inhibiting the production of these pain mediators."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Floctafenine","title":"Floctafenine","extract":"Floctafenine is a nonsteroidal anti-inflammatory drug (NSAID)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1178","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOCTAFENINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Floctafenine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T13:45:28.520357","biosimilars":[],"competitors":[{"drugName":"ziconotide","drugSlug":"ziconotide","fdaApproval":"2004-12-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methoxyflurane","drugSlug":"methoxyflurane","fdaApproval":"","relationship":"same-class"}],"genericName":"floctafenine","indications":{"approved":[{"name":"Acute pain","source":"DrugCentral","snomedId":274663001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ziconotide","brandName":"ziconotide","genericName":"ziconotide","approvalYear":"2004","relationship":"same-class"},{"drugId":"methoxyflurane","brandName":"methoxyflurane","genericName":"methoxyflurane","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003480","UNII":"O04HVX6A9Q","CHEBI":"CHEBI:31612","INN_ID":"2936","RXNORM":"4444","UMLSCUI":"C0016245","ChEMBL_ID":"CHEMBL2105075","KEGG_DRUG":"D01267","DRUGBANK_ID":"DB08976","PUBCHEM_CID":"3360","SECONDARY_CAS_RN":"36783-34-3","MESH_SUPPLEMENTAL_RECORD_UI":"C084600"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":60,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"N02BG04","allCodes":["N02BG04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 28","pmid":"41606487","title":"Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.","journal":"BMC cardiovascular disorders"},{"date":"2020 Oct 13","pmid":"33050924","title":"Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).","journal":"Trials"},{"date":"2019 Aug","pmid":"31185391","title":"Design, synthesis, modeling studies and biological screening of novel pyrazole derivatives as potential analgesic and anti-inflammatory agents.","journal":"Bioorganic chemistry"},{"date":"2019","pmid":"30417793","title":"Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity.","journal":"Current clinical pharmacology"},{"date":"2018 Mar 28","pmid":"29528082","title":"Iron-catalyzed ortho trifluoromethylation of anilines via picolinamide assisted photoinduced C-H functionalization.","journal":"Organic & biomolecular chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Idarac (FLOCTAFENINE) is a small molecule drug that targets Prostaglandin G/H synthase 1, a key enzyme involved in pain signaling. It is classified as a floctafenine and is used to treat acute pain. The commercial status of Idarac is currently unknown, and it has not been approved by the FDA. Idarac works by inhibiting the production of prostaglandins, which are chemical messengers that transmit pain signals to the brain. Further information on its pharmacokinetics and safety profile is not available.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}